Form 4: Gilead Sciences Executive Johanna Mercier Sells Shares Under 10b5-1 Trading Plan

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, sold 9,513 shares of common stock at $78.03 per share on August 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 28, 2024, Johanna Mercier, the Chief Commercial Officer of Gilead Sciences, sold 9,513 shares of the company's common stock.
• The sale was executed at a price of $78.03 per share.
• Following the transaction, Mercier directly owns 105,466 shares of Gilead Sciences.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on April 30, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. They can be part of a pre-planned diversification strategy or for personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• Executive compensation and stock ownership are common metrics used to compare companies within the biotechnology and pharmaceutical industries.
• Companies like Amgen (AMGN), AbbVie (ABBV), and Johnson & Johnson (JNJ) also have executives who regularly trade company stock under similar 10b5-1 plans.
• The size and frequency of these transactions can vary widely based on individual circumstances and company policies.

Stakeholder Impact

• The stock sale by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the pre-planned nature of the transaction.

Key Dates